Research programme: RNA based immunotherapeutics- RigontecAlternative Names: ImOl 200; ImOl 201; Retinoic acid inducible gene I receptor agonists - Rigontec
Latest Information Update: 08 Sep 2016
At a glance
- Originator Rigontec
- Class Gene therapies; Oligonucleotides; RNA; Small molecules
- Mechanism of Action DDX58 protein stimulants; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation; Viral infections